Coronavirus (COVID-19): visiting The Royal Marsden suspended

Coronavirus (COVID-19) latest: Visiting The Royal Marsden is still suspended, but we want to reassure our patients, their families and anyone worried about cancer during this difficult time that we are still delivering treatment - the hospital is open. Please see more information here about how we are keeping everyone safe.

Private Patients

We use leading edge genomic testing to help direct personalised treatment using the latest technology

Our portfolio of Next Generation Sequencing (NGS) panels and karyotype and Fluorescence In Situ Hybridisation (FISH) analysis for solid tumours and haematological malignancies allows us to identify diagnostic markers, treatment targets, and potential resistance mutations and provides a comprehensive overview of the tumour, helping to accurately support patient care and improve our understanding of cancer diagnostics. 
Multiple types of aberrations can be detected, including single nucleotide variants (SNV), complex insertion-deletions, gene copy number variation, gene rearrangements as well as measures including hypermutation, chromosome variation, tumour mutational burden (TMB) and microsatellite instability (MSI).  In addition, as part of our Haematological Malignancies Diagnostic Service we offer clonality assessment, mutational status of Ig Variable regions and translocation gene detection at diagnosis and as part of minimal residual disease work up. 

Our rapid circulating tumour DNA (ctDNA) testing service, analyses patient blood samples for genetic changes in fragments of tumour DNA found in the circulation. This liquid biopsy test is currently being used in non-small cell lung cancer at diagnosis, to determine if a patient's tumour has a mutation within the EGFR gene, and at progression, to determine resistance to therapy.

For further details of our panels, please contact us 

For all referrals, please contact Private Care

Refer to Private Care

How to refer